Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
Khi Pin ChuaYvonne H F TengAaron C TanAngela M TakanoJacob J S AlvarezRahul NaharNeha RohatgiGillianne G Y LaiZaw Win AungJoe P S YeongKiat Hon LimMarjan Mojtabavi NaeiniIrfahan KassamAmit JainWan Ling TanApoorva GognaChow Wei TooRavindran KanesvaranQuan Sing NgMei Kim AngTanujaa RajasekaranDevanand AnanthamGhee Chee PhuaBien Soo TanYin Yeng LeeLanying WangAudrey S M TeoAlexis Jiaying KhngMing Jie LimLisda SutejaChee Keong TohDarren Wan-Teck LimN Gopalakrishna IyerWai Leong TamEng-Huat TanWeiwei ZhaiAxel Maximilian HillmerAnders J SkanderupDaniel S W TanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our results illustrate the interplay between genetic alterations, cell lineage plasticity, and immune microenvironment in shaping divergent TKI resistance and outcome trajectories in EGFR-mutated NSCLC. Genomic and transcriptomic profiling may facilitate the design of bespoke therapeutic approaches tailored to a tumor's adaptive potential.
Keyphrases